Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Non-invasive diagnostic marker for liver cirrhosis related to chronic drug-induced liver injury and application of non-invasive diagnostic marker

A technology of drug-induced liver injury and diagnostic markers, applied in the field of metabolomics, can solve traumatic problems and achieve the effects of improving accuracy, stabilizing clinical application value, and dynamically monitoring disease progression

Pending Publication Date: 2020-12-15
THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Aiming at the disadvantages of invasiveness and invasiveness in the existing diagnostic methods for liver cirrhosis, the present invention provides a non-invasive diagnostic marker for liver cirrhosis associated with chronic drug-induced liver injury and its application, using the peak area ratio of two metabolites Carry out relative quantification in order to improve the applicability and robustness of candidate biomarkers, and provide a basis for early diagnosis of chronic drug-induced liver cirrhosis, which has nothing to do with which drugs cause early chronic drug-induced liver injury-related liver cirrhosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Non-invasive diagnostic marker for liver cirrhosis related to chronic drug-induced liver injury and application of non-invasive diagnostic marker
  • Non-invasive diagnostic marker for liver cirrhosis related to chronic drug-induced liver injury and application of non-invasive diagnostic marker
  • Non-invasive diagnostic marker for liver cirrhosis related to chronic drug-induced liver injury and application of non-invasive diagnostic marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] 1) Sample collection and processing:

[0048] The DILI serum samples stored in the -80°C refrigerator, including 34 serum samples in the chronic drug-induced liver injury group and 15 serum samples in the chronic drug-induced liver cirrhosis group, were divided into groups as follows: rethaw at 4°C, and precisely pipette 200 μL into EP tubes , add 3 times the amount of pre-cooled methanol to dilute, vortex and mix well, and at 4°C at 12000r·min -1 Centrifuge for 10min, use 1mL injection to absorb the supernatant, and pass through a 0.22μm microporous membrane.

[0049] 2) Phase chromatography mass spectrometry analysis and determination

[0050] The filtrate obtained in step 1) was subjected to liquid chromatography mass spectrometry analysis.

[0051] The instruments and reagents are as follows:

[0052] The instrument analysis platform is LC-Q-TOF / MS (1290infinity HPLC, 6550ifunnel Q-TOF / MS) and the separation column is ZORBAX SB 300 C18 (100mm×2.1, 1.8μm). The or...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a non-invasive diagnostic marker for liver cirrhosis related to chronic drug-induced liver injury and application of the non-invasive diagnostic marker. Every two of the five discovered metabolites are combined to construct a peak area ratio or absolute quantification of the peak areas of the metabolites, so that the five discovered metabolites can be used for distinguishing a chronic DILI liver cirrhosis group from a non-liver cirrhosis chronic DILI group. At present, liver puncture pathological examination is a gold standard for liver cirrhosis diagnosis, but the liver puncture pathological examination is related to patient compliance and patient contraindications, and sometimes is difficult to implement; and due to invasive examination, the method is difficult tobe used as a dynamic monitoring and early diagnosis method of the LC-DILI. The non-invasive diagnostic marker and the application thereof provided by the invention can replace common invasive liver puncture pathological examination at present, and have more stable clinical application value.

Description

technical field [0001] The invention relates to metabonomics technology, in particular to a non-invasive diagnostic marker for liver cirrhosis associated with chronic drug-induced liver injury and its application. Background technique [0002] Liver cirrhosis is one of the manifestations of drug-induced liver injury from the stage of acute inflammatory response and injury to the chronic stage and finally to the terminal stage. Due to the strong functional compensatory ability of the liver, patients with cirrhosis with chronic DILI in the compensated phase (LC-DILI) often have similar clinical features to patients with chronic DILI without cirrhosis (CH-DILI). Differences in indicators often have no clinical significance for distinguishing the two disease stages, and the result may lead to the progression of early compensated cirrhosis to decompensated cirrhosis, with a poor clinical prognosis. Liver puncture pathological examination is the gold standard for the diagnosis of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/88G01N30/02G01N30/06G01N30/72
CPCG01N30/88G01N30/02G01N30/06G01N30/72G01N2030/8822G01N2030/027G01N2030/062
Inventor 王伽伯牛明卫璐戈刘晓熠肖小河
Owner THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com